Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANJAY RASTOGI

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1003836602
CMS profile
160
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$337,065.29

425 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 6 of 9; records 251–300 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANJAY RASTOGI

NPI 1003836602 · CMS profile ID 160

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 9; records 251–300 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 9; records 251–300 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 9; records 251–300 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANJAY RASTOGI, NPI 1003836602, CMS profile ID 160, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 9; records 251–300 of 425 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1003836602?year=2022&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

425 matching records · $337,065.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 425 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 425.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Fresenius USA Marketing, Inc. $61.3705/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954550701 CMS
Fresenius USA Marketing, Inc. $120.0005/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954550761 CMS
Fresenius USA Marketing, Inc. $121.7905/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954550773 CMS
Fresenius USA Marketing, Inc. $141.5705/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954550797 CMS
Fresenius USA Marketing, Inc. $316.0805/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954566977 CMS
Fresenius USA Marketing, Inc. $997.7105/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954567053 CMS
Fresenius USA Marketing, Inc. $3,000.0005/10/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954567123 CMS
Vifor Pharma, Inc. $71.4405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896740173 CMS
AstraZeneca Pharmaceuticals LP $130.1705/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914773241 CMS
SANOFI-AVENTIS U.S. LLC $86.7705/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965549221 CMS
Alexion Pharmaceuticals, Inc. $106.9704/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915746717 CMS
AstraZeneca Pharmaceuticals LP $2,000.0004/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915570855 CMS
AstraZeneca Pharmaceuticals LP $100.0004/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914995455 CMS
Bayer HealthCare Pharmaceuticals Inc. $6,660.0004/18/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930250011 CMS
Amicus Therapeutics, Inc. $24.4604/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957636325 CMS
Bayer HealthCare Pharmaceuticals Inc. $80.0004/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929965233 CMS
Bayer HealthCare Pharmaceuticals Inc. $7,215.0004/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930018151 CMS
Bayer HealthCare Pharmaceuticals Inc. $722.0004/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930109679 CMS
Horizon Therapeutics plc $92.6504/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937679045 CMS
Vifor Pharma, Inc. $1,900.0004/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896744303 CMS
Bayer HealthCare Pharmaceuticals Inc. $332.0004/12/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930015409 CMS
Bayer HealthCare Pharmaceuticals Inc. $33.0604/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929938015 CMS
Bayer HealthCare Pharmaceuticals Inc. $92.6404/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965547019 CMS
Vifor Pharma, Inc. $81.3704/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896740179 CMS
Bayer HealthCare Pharmaceuticals Inc. $3,330.0004/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929931061 CMS
Vifor Pharma, Inc. $20.8104/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896740119 CMS
Vifor Pharma, Inc. $20.8104/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896740121 CMS
Vifor Pharma, Inc. $120.6504/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896744225 CMS
AstraZeneca Pharmaceuticals LP $1,000.0004/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915138553 CMS
AstraZeneca Pharmaceuticals LP $4,000.0004/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914786377 CMS
AstraZeneca Pharmaceuticals LP $764.0004/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915219687 CMS
AstraZeneca Pharmaceuticals LP $100.0004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915489911 CMS
AstraZeneca Pharmaceuticals LP $100.0004/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915837393 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.0504/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929967877 CMS
Bayer HealthCare Pharmaceuticals Inc. $120.0004/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929977541 CMS
Bayer HealthCare Pharmaceuticals Inc. $25.0004/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930230503 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,274.1104/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930086943 CMS
Bayer HealthCare Pharmaceuticals Inc. $807.0604/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929979717 CMS
Bayer HealthCare Pharmaceuticals Inc. $722.0003/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930200779 CMS
Baxter Healthcare $157.5003/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 883138061 CMS
AstraZeneca Pharmaceuticals LP $86.4303/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914627471 CMS
AstraZeneca Pharmaceuticals LP $353.3703/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914867555 CMS
AstraZeneca Pharmaceuticals LP $125.0003/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914900999 CMS
AstraZeneca Pharmaceuticals LP $994.6603/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915520617 CMS
AstraZeneca Pharmaceuticals LP $377.5703/29/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915601761 CMS
Bayer HealthCare Pharmaceuticals Inc. $107.1003/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930116233 CMS
Bayer HealthCare Pharmaceuticals Inc. $107.1003/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929951227 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,797.7503/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929987339 CMS
Bayer HealthCare Pharmaceuticals Inc. $286.3503/25/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930053319 CMS
Amicus Therapeutics, Inc. $87.9803/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957636575 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $336,170.10 533
PY2020 $192,175.63 255
PY2021 $291,173.13 321
PY2022 $337,065.29 425
PY2023 $322,806.85 416
PY2024 $375,489.21 442
PY2025 $309,678.31 349

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,471.25 2
PY2025 Principal investigator $153,970.40 25
PY2024 Principal investigator $723,946.24 24
PY2023 Principal investigator $207,737.80 16
PY2022 Principal investigator $353,966.14 40
PY2021 Principal investigator $458,915.15 51
PY2020 Recipient $11,262.55 1
PY2020 Principal investigator $766,044.51 122
PY2019 Recipient $934.24 11
PY2019 Principal investigator $1,475,303.92 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $10,055.00 12/08/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142633
Principal investigator 1 GENZYME CORPORATION $3,692.00 10/20/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226155810
Recipient Novartis Pharmaceuticals Corporation $4,337.00 10/20/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293286
Principal investigator 1 GENZYME CORPORATION $500.00 10/14/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226155806
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $1,038.69 10/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants No dispute reported 06/30/2026 1214125080
Principal investigator 1 GENZYME CORPORATION $1,000.00 09/29/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226155800
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,332.89 09/25/2025 Non-covered Recipient Entity
The Regents Of The Univ Of California
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225414736
Principal investigator 1 GENZYME CORPORATION $3,726.00 09/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142563
Principal investigator 1 GENZYME CORPORATION $4,851.00 09/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142568
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $64,771.28 08/26/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Study to Determine the Prevalence, Demographic, and Clinical Characteristics Associated With PKD1 Variant Groups in Individuals Diagnosed With ADPKD No dispute reported 06/30/2026 1214124212
Principal investigator 1 GENZYME CORPORATION $2,368.60 08/25/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226155796
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $283.50 07/24/2025 Non-covered Recipient Entity
The Regents Of The Univ Of California
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413336
Principal investigator 1 GENZYME CORPORATION $1,000.00 07/07/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226156185
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $283.50 07/03/2025 Non-covered Recipient Entity
The Regents Of The Univ Of California
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413264
Principal investigator 1 GENZYME CORPORATION $7,142.00 06/09/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142524
Principal investigator 1 GENZYME CORPORATION $24,328.00 06/09/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226156111
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,816.29 05/30/2025 Non-covered Recipient Entity
The Regents Of The Univ Of California
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412772
Recipient Novartis Pharmaceuticals Corporation $6,134.25 05/21/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293290
Principal investigator 1 GENZYME CORPORATION $750.00 05/05/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226156090
Principal investigator 1 GENZYME CORPORATION $5,546.00 04/28/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142502
Principal investigator 1 GENZYME CORPORATION $4,686.00 03/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226142482
Principal investigator 1 GENZYME CORPORATION $4,802.20 03/17/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226156025
Principal investigator 1 GENZYME CORPORATION $750.00 03/17/2025 Non-covered Recipient Entity
New York Medical College Office Of Research Administration Skyline Rm J23
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226156031
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,772.19 03/06/2025 Non-covered Recipient Entity
The Regents Of The Univ Of California
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic No dispute reported 06/30/2026 1225404840
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,448.00 02/04/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190293375
Principal investigator 1 Novartis Pharmaceuticals Corporation $184.26 01/09/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA AT LOS ANGELES
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190302553
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $3,843.00 01/07/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1214124210